期刊文献+

PD-1和PD-L1与胃癌患者预后相关性的Meta分析 被引量:4

Prognostic Role of PD-1 and PD-L1 Expression in Gastric Cancer Patients: A Meta-analysis
下载PDF
导出
摘要 目的系统评价PD-1和PD-L1的表达对胃癌患者预后的影响。方法对PubMed、Web of Science、Cochrane Library、中国生物医学数据库(CBM)、Embase、中国知网(CNKI)等数据库进行文献检索。纳入研究为PD-1/PD-L1表达与胃癌患者预后关系的队列研究。采用RevMan 5.3软件对总生存期(OS)进行Meta分析。结果共纳入10项(3 093例胃癌患者)符合条件的队列研究。单因素和多因素分析显示,PD-1和PD-L1的表达与胃癌患者预后无明显相关性,PD-1的高表达与淋巴结转移(N^+)有显著相关性,PD-L1的高表达与胃癌晚期(Ⅲ~Ⅳ)有显著相关性。结论 PD-1和PD-L1表达与胃癌患者预后无明显相关性。 Objective To systematically evaluate the effect of PD-1 and PD-L1 expression on the prognosis of gastric cancer patients.Methods A comprehensive literature review was conducted in PubMed,Web of Science,Cochrane Library,China Biology Medicine Database(CBM),Embase and China National Knowledge Infrastructure(CNKI)databases.The cohort studies about the association of PD-1 and PD-L1 expression with the prognosis of GC patients were identified and included.RevMan 5.3 software was used to perform the meta-analysis for overall survival(OS).Results We included 10 eligible cohort studies comprising 3093 patients with GC.Univariate and multivariate analyses indicated no significant correlation of PD-1 and PD-L1 expression with the prognosis of GC patients,however,high PD-L1 and PD-1 expression were significantly correlated with advanced stages(Ⅲ-Ⅳ)of GC and lymph node metastasis(N^+),respectively.Conclusion There is no significant correlation of PD-1 and PD-L1 expression with the prognosis of gastric cancer patients.
作者 王玉丰 姚南 王军 闵光涛 WANG Yufeng;YAO Nan;WANG Jun;MIN Guangtao(The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of General Surgery,The First Hospital of Lanzhou University,Lanzhou 730000,China)
出处 《肿瘤防治研究》 CAS CSCD 2020年第5期346-352,共7页 Cancer Research on Prevention and Treatment
基金 兰州大学第一医院院内基金(ldyyyn2018-57)。
关键词 PD-1 PD-L1 胃癌 预后 META分析 PD-1 PD-L1 Gastric cancer Prognostic Meta-analysis
  • 相关文献

参考文献2

二级参考文献138

  • 1Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Globalcancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID:21296855 DOI: 10.3322/caac.20107]. 被引量:1
  • 2Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D.Explaining gastric cancer survival differences among Europeancountries. Int J Cancer 2004; 109: 737-741 [PMID: 14999783DOI: 10.1002/ijc.20047]. 被引量:1
  • 3Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A,Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer.Cochrane Database Syst Rev 2010; (3): CD004064 [PMID:20238327 DOI: 10.1002/14651858.CD004064.pub3]. 被引量:1
  • 4Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M,Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C,Van Cutsem E. Clinical benefit with docetaxel plus fluorouraciland cisplatin compared with cisplatin and fluorouracil in aphase III trial of advanced gastric or gastroesophageal canceradenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25:3205-3209 [PMID: 17664467]. 被引量:1
  • 5Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L,Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G,Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumabin combination with chemotherapy versus chemotherapy alone fortreatment of HER2-positive advanced gastric or gastro-oesophagealjunction cancer (ToGA): a phase 3, open-label, randomisedcontrolled trial. Lancet 2010; 376: 687-697 [PMID: 20728210DOI: 10.1016/S0140-6736(10)61121-X]. 被引量:1
  • 6Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, ShimadaY, Hironaka S, Sugimoto N, Lipatov O, Kim TY, CunninghamD, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, FerryD, Chandrawansa K, Schwartz JD, Ohtsu A. Ramucirumabplus paclitaxel versus placebo plus paclitaxel in patients withpreviously treated advanced gastric or gastro-oesophageal junctionadenocarcinoma (RAINBOW): a double-blind, randomised phase3 trial. Lancet Oncol 2014; 15: 1224-1235 [PMID: 25240821 DOI:10.1016/S1470-2045(14)70420-6]. 被引量:1
  • 7Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem1990; 265: 7709-7712 [PMID: 2186024]. 被引量:1
  • 8Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensivepathway map of epidermal growth factor receptor signaling. MolSyst Biol 2005; 1: 2005.0010 [PMID: 16729045]. 被引量:1
  • 9Barnham KJ, Torres AM, Alewood D, Alewood PF, DomagalaT, Nice EC, Norton RS. Role of the 6-20 disulfide bridge in thestructure and activity of epidermal growth factor. Protein Sci 1998;7: 1738-1749 [PMID: 10082370 DOI: 10.1002/pro.5560070808]. 被引量:1
  • 10Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A,Busch R, Hermannst-dter C, N-hrig J, Becker KF, Becker I, H-flerH, Fend F, Luber B. Epidermal growth factor receptor expressioncorrelates with poor survival in gastric adenocarcinoma fromMexican patients: a multivariate analysis using a standardizedimmunohistochemical detection system. Mod Pathol 2004; 17:579-587 [PMID: 15073595 DOI: 10.1038/modpathol.3800085]. 被引量:1

共引文献20

同被引文献40

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部